Protective effects of medicinal plant-derived metabolites in cardiovascular disease targeting exosomal pathways

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Cardiovascular disease (CVD) is a highly prevalent and lethal disease worldwide, and existing conventional therapeutic drugs have limitations due to their side effects. Medicinal plant-derived metabolites have become a research hotspot due to their multi-target and multi-pathway cardioprotective potentials, while exosomal miRNAs, as core regulatory molecules of intercellular communication, play a key role in CVD such as atherosclerosis and myocardial infarction. This paper systematically reviews the mechanisms by which medicinal plant-derived metabolites regulate exosome miRNA or synergize with exosome therapy to protect CVD. For instance, Tanshinone IIA, Astragaloside IV, Paeonol, and Ginsenoside Rg1 can achieve effects such as promoting/inhibiting angiogenesis, anti-inflammation, and vascular remodeling by regulating exosomal miRNA expression. Finally, we look forward to the future direction of Medicinal plant-derived metabolites combined with exosomes in the protection of cardiovascular diseases, and provide a theoretical basis for the application of Medicinal plant-derived metabolites in CVD protection and the development of exosomal miRNA-targeted drugs.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.